Investigational treatments for cytomegalovirus infection in phase I and II study [0.03%]
I期和II期临床试验的治疗巨细胞病毒感染的 investigational治疗方法
Morgan Hakki,Anat Stern,Genovefa A Papanicolaou
Morgan Hakki
Introduction: The additions of letermovir and maribavir to the cytomegalovirus (CMV) armamentarium have markedly changed the landscape of CMV prevention and treatment in transplant recipients. However, their currently app...
New investigational agents for the treatment of clostridioides difficile infections [0.03%]
用于治疗艰难梭菌感染的新 investigational 代理机构
Mai-Chi N Tran,Taryn A Eubank,Ravina Kullar et al.
Mai-Chi N Tran et al.
Introduction: The Centers for Disease Control and Prevention (CDC), estimates that Clostridioides difficile infection (CDI) results in 250,000 hospitalizations yearly in the U.S.A. an annual mortality of 12,800 and recurr...
Slobodan M Janković
Slobodan M Janković
Introduction: Although innovative ways of treating epilepsy that is resistant to standard therapy are actively being researched, not many have demonstrated sufficient efficacy and safety in clinical research to obtain mar...
An update on novel investigational agents for the treatment of primary biliary cholangitis [0.03%]
治疗原发性胆汁性胆管炎的新型 investigational药物最新研究进展报告摘要
Annarosa Floreani,Daniela Gabbia,Sara De Martin
Annarosa Floreani
Introduction: Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by progressive bile duct destruction that can lead to liver cirrhosis and liver failure. While ursodeoxycholic acid (UDCA...
IRAK signaling in cancers: mechanisms, targeting, and clinical implications [0.03%]
癌变中的IRA克信号转导：机制、靶向和临床意义
Eric J Vick,Daniel T Starczynowski
Eric J Vick
Introduction: All human cells have the capacity to respond to damage or danger through conserved signaling pathways that converge on interleukin-1 receptor-associated kinases (IRAKs). IRAKs are a family of kinases that pl...
Androgen receptor pathway signaling inhibitors in development for prostate cancer therapy [0.03%]
在研的前列腺癌治疗中的雄激素受体通路信号抑制剂
Sara Bleve,Pier Vitale Nuzzo,Abdul Baseet Arham et al.
Sara Bleve et al.
Introduction: Prostate cancer (PC), including castration-resistant disease (CRPC), remains largely driven by dysregulated androgen receptor (AR) signaling. While androgen deprivation therapy (ADT) combined with next-gener...
Pharmacokinetics, pharmacodynamics, and safety of HE009, a novel selective S1P1 receptor modulator, in healthy Chinese subjects [0.03%]
HE009的药代动力学、药效学及在中国健康志愿者中的安全性研究
Jie Ding,Qian Zhang,Qin Yang et al.
Jie Ding et al.
Objective: HE009,a novel selective sphingosine-1-phosphate receptor-1(S1P1) modulator, was evaluated in healthy Chinese subjects to assess itspharmacokinetics, pharmacodynamics, and safety profile. ...
Emerging ANGPTL3-directed therapies for hyperlipidemia: insights from two recent phase II trials [0.03%]
ANGPTL3靶向治疗高脂血症的新兴疗法：两项二期临床试验的新见解
Amanda J Hooper,Thusyanthy Parameswaran,John R Burnett
Amanda J Hooper
Development of investigational radiotherapeutics for the diagnosis and treatment of glioma [0.03%]
胶质瘤诊断和治疗的研究放射治疗的开发
Yuhao Shi,Sravya Koduri,Jonathan T Yang et al.
Yuhao Shi et al.
Introduction: Gliomas are tumors that arise from glial cells in the central nervous system. Radiation provides local control for low grade gliomas and improves survival for patients with high grade gliomas; however, recur...
Mirdametinib, an FDA-Approved MEK1/2 inhibitor for adult and pediatric NF1-associated plexiform neurofibromas [0.03%]
米拉达 metib 和 FDA 批准的 MEK1/2 抑制剂，用于成人和儿科患者的 I 型神经纤维瘤病相关的丛状神经纤维瘤
Gorkem Oztosun,Amy Armstrong,Angela C Hirbe
Gorkem Oztosun
Introduction: Neurofibromatosis type 1 (NF1) is an autosomal-dominant cancer predisposition syndrome that leads to the development of plexiform neurofibromas (PNs), which can cause significant morbidity and are at risk to...